Tongmai Jiangzhuo Granules: A Promising Solution for Hyperuricemia-Related NAFLD

Introduction: Tongmai Jiangzhuo Granules (TMJZ), derived from clinical prac-tice, have the function of lowering uric acid in clinical settings and have the potential to protect the liver. In this study, lipid metabolomics and other technologies were used to reveal the mechanism of TMJZ on the hepatoprotective effect in hyperuricemia-related NAFLD mice. Methods: The efficacy of TMJZ in hepatoprotective effect was evaluated by lipid levels, liver function, and liver pathology in mice. LC-MS lipidomics and PLC-DA analysis were used to explore TMJZ's effects on liver lipid metabolism and to identify affected pathways. Key proteins involved in glycerophospholipid metabolism were verified using ELISA and Western blot. Finally, components of TMJZ were identified by LC-MS. Results: TMJZ significantly reduced uric acid levels and lowered serum TC, TG, LDL-c, ALT, and AST in model mice. Histopathological analysis indicated that TMJZ decreased liver weight and improved liver fatty lesions. Lipid metabolomics showed that TMJZ ad-ministration could change the proportions of the main lipid components, including glycer-ophospholipids, glycerides, sphingolipids, fatty acids, and glycolipids, in the liver. TMJZ could increase LCAT and PLA2 levels and decrease LPCAT3 levels. Meanwhile, 533 com-ponents of TMJZ were detected by LC-MS analysis, including Berberine and Salvianolic acid A. Discussion: LCAT, LP-PLA2, and LPCAT3 played essential roles in lipid components, phospholipid biosynthesis, and catabolism, which might be the promising solution of TMJZA for Hyperuricemia-related NAFLD. Conclusion: TMJZ exhibits a favorable anti-NAFLD effect. Its mechanism may involve increasing LCAT and PLA2, decreasing LPCAT3, and regulating the glycerophospholipid metabolism pathway.